From: Focused allergic rhinitis practice parameter for Canada
Systematic Reviews | Randomized Controlled Trials | |||||
---|---|---|---|---|---|---|
Clinical Practice Guidelines | OAH & INCS | OAH | INCS | OAH & INCS | OAH | INCS |
Brożek et al., 2017 [56] | Juel-Berg et al., 2017 [62] | Huang et al., 2019 [61] | Donaldson et al., 2020 [57] | Wartna et al., 2017 [82] | Hashiguchi et al., 2017 [59] | Ellis et al., 2016 [58] |
Dykewicz et al., 2017 [4] | Meltzer et al., 2021 [67] | Liu et al., 2018 [65] | Hoang et al., 2022 [60] | Locks et al., 2017 [66] | Karaulov et al., 2019 [63] | |
Dykewicz et al., 2020 [5] | Zhang et al., 2022 [88] | Miligkos et al., 2021 [68] | Khattiyawittayakun et al., 2019 [64] | Nayak et al., 2017 [69] | Ng et al., 2021 [70] | |
Scadding et al., 2017 [40] | Singh Randhawa et al., 2021 [77] | Phinyo et al., 2022 [76] | Nourollahian et al., 2020 [71] | Noyama et al., 2016 [73] | ||
Wise et al., 2018 [50] | Tiamkao et al., 2021 [79] | Valenzuela et al., 2019 [80] | Novak et al., 2016 [72] | Thongngarm et al., 2021 [78] | ||
Velentza et al., 2020 [81] | Wu et al., 2019 [84] | Okubo et al., 2019 [75] | Zieglmayer et al., 2020 [90] | |||
Wei, 2016 [83] | Okubo et al., 2017 [74] | Zhang et al., 2021 [89] | ||||
Xiao et al., 2016 [85] | Yamprasert et al., 2020 [86] | |||||
Yonekura et al., 2019 [87] |